《大行報告》瑞銀首予泰格醫藥(03347.HK)「買入」評級 目標價149元
瑞銀發表報告,首次覆蓋研究泰格醫藥(03347.HK),予其股份「買入」評級,目標價149元。
瑞銀表示,今年對泰格而言是困難的一年,因其臨床試驗的營運直接受到新型冠狀病毒疫情影響。不過,該行對集團的長期看法正面,認為其仍在快速增長的臨床試驗服務市場有優勢,並持續改善技術以追上國際標準。
該行估計,泰格醫藥今年的收入可按年增長13%,2020年至2024年的年均複合增長率料為27%。另外,由於受到投資的公司及股票基金的一次性公平值收益影響,瑞銀認為集團今明兩年盈利增長的指標性較低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.